Trial Profile
A Phase 2 Safety and Efficacy Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Jun 2013
Price :
$35
*
At a glance
- Drugs Pacritinib (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Hodgkin's disease; Mantle-cell lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 28 Jun 2013 Pooled safety results of this trial and 3 other phase I and II trials will be presented at the 18th Congress of the European Hematology Association in June 2013. Results also published in a Cell Therapeutics media release.
- 29 Nov 2012 New source identified and integrated (M.D. Anderson Cancer Center: 2010-0492).
- 19 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.